GelMEDIX, Inc.

GelMEDIX develops innovative ocular cell therapies aimed at enhancing vision restoration for individuals afflicted by ocular diseases. Their advanced formulations focus on improving cell viability and tissue regeneration. GelMEDIX Inc. specializes in creating ocular cell therapies to address vision impairment caused by retinal damage.

Founded in 2020, the company is headquartered in Cambridge, US. In February 2026, GelMEDIX, Inc. raised USD 13 million in seed funding led by Safar Partners, with participation from HTL S. A.

S. , Beacon Angels, Boston Harbor Angels, and TiE Angels. The details surrounding the founder are not provided. GelMEDIX, Inc.

specializes in ocular cell therapy, focusing on engineering innovative formulations designed to enhance cell viability, engraftment, and tissue regeneration, ultimately aiming to restore vision for individuals suffering from various ocular diseases. The company’s core offerings revolve around advanced therapeutic solutions that address critical challenges in ocular health, particularly targeting conditions that compromise vision due to retinal damage or degeneration. GelMEDIX’s products are positioned for clinical applications and are developed to cater to healthcare providers, including hospitals, specialty clinics, and research institutions. The therapeutic formulations are primarily designed for markets in North America and Europe, where there is a pressing need for effective treatments in the ocular space, particularly for age-related macular degeneration and other degenerative retinal diseases.

The revenue structure of GelMEDIX, Inc. is predicated on direct business-to-business transactions with healthcare providers and research institutions that are interested in cutting-edge ocular therapies. Transactions occur through partnerships and collaborations, with potential licensing agreements that facilitate the distribution and use of their innovative therapeutic products. Specific pricing plans and revenue details are not disclosed, but the company’s revenue streams include one-time fees for therapy applications and ongoing support or subscription-based models for continuous access to their products and research findings.

The focus on flagship therapeutic offerings ensures that GelMEDIX can build a sustainable revenue model around the demand for effective ocular cell therapies within the healthcare sector. The company will use the October 2025 funding to support the development of new ocular therapies and expand their market presence. The company plans to introduce additional products aimed at age-related macular degeneration and other ocular conditions, with a focus on enhancing their therapeutic formulations by 2026. Furthermore, GelMEDIX is strategizing to penetrate new markets in Europe by mid-2026, aligning with their ongoing commitment to address the growing demand for effective ocular treatments.